Related Experiment Video
Updated: Feb 7, 2026

Analysis of Volatile and Oxidation Sensitive Compounds Using a Cold Inlet System and Electron Impact Mass Spectrometry
Published on: September 5, 2014
The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists
Abstract:
Medication compounding gained national attention in the fall of 2012 after contaminated compounded medications produced in the New England Compounding Center infected 800 people with fungal meningitis and led to several fatalities. This prompted Congress to pass regulations on compounding through the Drug Quality and Security Act (DQSA) in 2013. The act increased oversight of patient-specific drug compounding taking place in compounding pharmacies, created 503(b) outsourcing facilities to obtain compounded drugs, and added regulations for obtaining compounded drugs from traditional 503(a) pharmacies. These regulations also had a broader overall impact by triggering federal and state-specific policies, which have ultimately limited a physician's ability to perform low-risk, in-office compounding. This article provides an overview of the different types of compounding restrictions, reviews the current federal and state regulations and/or guidelines, discusses how newly proposed policies may affect the practice of dermatology, and presents an algorithm on how the practicing dermatologist should approach compounding. J Drugs Dermatol. 2018;17(7 Suppl):s17-22.
Insights
The 2013 Drug Quality and Security Act (DQSA) increased oversight of drug compounding following a meningitis outbreak. However, these regulations have limited physicians
Area of Science:
- Pharmaceutical Sciences
- Regulatory Affairs
- Dermatology Practice
Background:
- A 2012 fungal meningitis outbreak linked to contaminated compounded medications highlighted safety concerns.
- The New England Compounding Center incident led to significant regulatory changes in drug compounding.
Purpose of the Study:
- To provide an overview of compounding restrictions following the DQSA.
- To review current federal and state regulations impacting drug compounding.
- To discuss the potential effects of new policies on dermatology and offer a practical algorithm for dermatologists.
Main Methods:
- Review of federal and state regulations and guidelines concerning medication compounding.
- Analysis of the impact of the Drug Quality and Security Act (DQSA) of 2013.
- Discussion of proposed policy changes and their implications for dermatological practice.
Main Results:
- The DQSA of 2013 enhanced oversight of compounding pharmacies and established 503(b) outsourcing facilities.
- Federal and state policies, influenced by the DQSA, have restricted physicians' ability to perform in-office compounding.
Conclusions:
- Recent regulations have significantly altered the landscape of medication compounding.
- Dermatologists face limitations in performing in-office compounding due to evolving policies.
- Guidance is needed for dermatologists to navigate compounding regulations effectively.
Related Concept Videos
Molecules and Compounds
Organic Compounds
Elements and Compounds
Elements
Elements are classified as atomic or molecular based on the nature of their basic units. They are unique forms of matter with specific chemical and physical properties that cannot break down into smaller substances by ordinary chemical reactions. There...
Solubility of Ionic Compounds
Classification of Elements and Compounds
Compounds are pure substances composed of two or more elements in fixed, definite proportions. Compounds are classified as ionic or molecular (covalent) based on the bonds...
Coordination Compounds and Nomenclature

